A Novel & Differentiated Approach to Targeted Protein Degradation – Leveraging the Ubiquitin Conjugating Enzyme (E2) Family
Time: 10:00 am
day: Research Day
Details:
- Ubiquitin Conjugating Enzymes are challenging to modulate pharmacologically using small molecules due to lack of druggable pockets
- Fragment Based Drug Design for the Modified (PTM) – E2 complex enabled discovery of first in class ligands
- Through E2 ligand extension and molecular design, efficacious bi-functional degraders have been developed for multiple proteins of interest
